HPBCD can cross the Brain-Blood Barrier
Matencio et al. reported in their recent paper that 92.8% of HPBCD administered intrathecally to a child suffering from Niemann
A forum for researchers, students and applicants in the field of cyclodextrin technology
Matencio et al. reported in their recent paper that 92.8% of HPBCD administered intrathecally to a child suffering from Niemann